Generalised anxiety disorder

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 1 Phase II/III: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Definium Therapeutics US Inc. Commercial
    LYSERGIDE
    2024-513572-17-00 4 countries 2025 n=201
    Ended

Phase II/III

1 trial
  • Otsuka Pharmaceutical Development & Commercialization Inc. Commercial
    ULOTARONT
    2022-502077-42-00 6 countries 2023 n=255
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Otsuka Pharmaceutical Development & Commercialization Inc. Commercial 1 Phase II/III 0
Definium Therapeutics US Inc. Commercial 1 Phase III 0
New trials by year
2023
1
2025
1
← All indication landscapes